Rosacea is a chronic inflammatory dermatosis affecting approximately 5% of the adult population, characterized by recurrent episodes of facial flushing, persistent erythema, telangiectasias, and in some phenotypes, inflammatory papules and pustules. The erythematotelangiectatic subtype, which presents primarily with vascular manifestations including persistent centrofacial erythema and visible telangiectasias, poses particular management challenges due to the limited efficacy of traditional topical and systemic therapies in addressing these structural vascular changes.

At The Pur Health, Dr. Munib's approach to rosacea management recognizes that while pharmacologic interventions can modulate inflammatory responses and reduce pustular lesions, the persistent vascular component requires targeted treatment of the abnormal cutaneous vasculature. Intense pulsed light therapy has emerged as an evidence-based intervention for erythematotelangiectatic rosacea, offering a mechanism-based approach to reducing both visible telangiectasias and diffuse erythema through selective photothermolysis of dilated blood vessels.

The vascular manifestations of rosacea result from a complex interplay of neurovascular dysregulation, chronic inflammation, and structural alterations in the cutaneous microvasculature. Research has identified several key pathophysiologic mechanisms contributing to the persistent erythema and telangiectasias characteristic of erythematotelangiectatic rosacea, including abnormal vasodilation mediated by sensory neuropeptides, increased expression of vascular endothelial growth factor promoting angiogenesis, chronic activation of innate immune responses leading to sustained inflammation, and structural remodeling of blood vessel walls resulting in permanent dilation.

The presence of dilated and tortuous blood vessels in the papillary dermis creates the visible redness and telangiectasias that define the erythematotelangiectatic phenotype. These vascular changes are not simply cosmetic concerns but represent underlying pathology that can progress over time if left unaddressed. Understanding this pathophysiology is essential for selecting appropriate interventions, as treatments must target not only the inflammatory component but also the structural vascular abnormalities that persist despite anti-inflammatory therapy.

The chronic nature of rosacea, combined with the limited ability of topical agents to reverse established vascular dilation, has led to increasing interest in light-based therapies that can directly address the vascular pathology. By selectively targeting hemoglobin in abnormal blood vessels, these treatments offer a pathophysiology-driven approach to managing the most visible and treatment-resistant aspects of erythematotelangiectatic rosacea.

Intense pulsed light therapy operates on the principle of selective photothermolysis, a concept introduced by Anderson and Parrish that describes the selective destruction of specific tissue targets through controlled delivery of optical energy. IPL systems emit broad-spectrum light in the visible and near-infrared range, typically between 500 and 1200 nanometers, with specific wavelengths selected through the use of cutoff filters to optimize absorption by the target chromophore while minimizing damage to surrounding tissue.

In the treatment of rosacea, the primary chromophore is oxyhemoglobin within the dilated blood vessels. Wavelengths in the 500 to 600 nanometer range correspond to absorption peaks of oxyhemoglobin, allowing for efficient energy transfer to the blood within telangiectatic vessels. The absorbed light energy converts to heat, raising the temperature of the blood and the vessel wall to a threshold at which thermal damage occurs. This controlled injury triggers coagulation of the vessel lumen and damage to the endothelial lining, leading to vessel collapse and eventual resorption by the body's natural healing processes.

The pulse duration and energy fluence must be carefully calibrated to achieve sufficient heating of the target vessel while avoiding thermal diffusion to adjacent structures. Contemporary IPL systems utilize pulse durations in the millisecond range with delay times between sequential pulses, allowing for selective heating of vessels of varying diameter while protecting the epidermis through contact cooling. Studies examining the optimal parameters for vascular lesions in rosacea have identified fluences ranging from 14 to 32 joules per square centimeter as effective, with pulse widths typically between 3.0 and 4.5 milliseconds and delay times of 30 to 40 milliseconds optimizing therapeutic efficacy while minimizing adverse effects.

Beyond the direct vascular effects, emerging evidence suggests that IPL may exert anti-inflammatory actions through mechanisms including mast cell stabilization and reduction of inflammatory mediators. Research has demonstrated that IPL treatment reduces the expression of inflammatory cytokines and stabilizes mast cells in rosacea-affected skin, potentially explaining the improvement in baseline erythema beyond what would be expected from vascular closure alone. This dual mechanism—addressing both the structural vascular abnormalities and the inflammatory milieu—may account for the sustained improvement observed in treated patients.

Multiple clinical studies have evaluated the efficacy of IPL therapy for erythematotelangiectatic rosacea, with consistent evidence supporting significant improvement in both erythema and visible telangiectasias. A landmark study published in the British Journal of Dermatology evaluated IPL treatment in patients with rosacea and demonstrated significant and long-lasting improvement in erythema and telangiectasia scores. The study reported that improvements were maintained for at least six months following treatment completion, indicating that IPL produces durable changes in the cutaneous vasculature rather than transient suppression of symptoms.

Systematic reviews examining interventions for rosacea have included IPL among the evidence-based treatment options for the erythematotelangiectatic phenotype. A comprehensive review using GRADE methodology to assess the quality of evidence concluded that IPL demonstrates efficacy for persistent erythema and telangiectasias, particularly in patients who have not responded adequately to topical therapies. The evidence base continues to expand, with recent studies utilizing standardized outcome measures and dermoscopic assessment to document vascular changes objectively.

Research comparing different IPL systems has demonstrated that both narrow-band devices utilizing wavelengths specifically targeting vascular chromophores and broad-band systems with appropriate filtering achieve significant improvement in rosacea symptoms. Studies have shown that vascular-specific wavelength bands in the 530 to 650 nanometer range, combined with longer wavelengths to provide deeper penetration, optimize results for mixed vascular lesions. The choice of device and parameters should be individualized based on the patient's skin type, the predominant vascular pattern, and the severity of erythema.

Clinical trials examining combined therapeutic approaches have also yielded promising results. Studies evaluating IPL in combination with topical agents such as tranexamic acid or photodynamic therapy with aminolevulinic acid have reported enhanced efficacy compared to IPL monotherapy in select cases. These combination approaches may be particularly valuable for patients with concurrent inflammatory features or those with refractory erythema, though they require careful patient selection and monitoring for potential adverse effects.

Standardized treatment protocols for IPL therapy in rosacea typically involve three to four sessions spaced three to four weeks apart. This interval allows for resolution of acute inflammatory responses from the previous treatment and clearance of damaged vascular structures before subsequent intervention. The spacing also permits clinical assessment of treatment response, allowing for parameter adjustments if needed to optimize outcomes while minimizing adverse effects.

Device settings must be customized based on several patient-specific factors, including Fitzpatrick skin type, degree of baseline erythema, pattern and caliber of telangiectasias, and history of previous vascular treatments. For patients with lighter skin types and prominent telangiectasias, higher fluences and shorter wavelengths may be appropriate to achieve adequate vessel coagulation. Conversely, patients with darker skin tones require more conservative energy settings and longer wavelengths to reduce the risk of epidermal injury and post-inflammatory hyperpigmentation.

Treatment technique involves full-face irradiation with additional spot treatment for particularly prominent telangiectasias. Overlapping pulses ensure complete coverage of affected areas, though care must be taken to avoid excessive overlap that could result in confluent thermal injury and increased risk of adverse effects. Contact cooling using chilled gel or sapphire cooling tips protects the epidermis and improves patient comfort during treatment. Some practitioners employ a test spot approach, treating a small area and assessing the immediate and delayed response before proceeding with full-face treatment, particularly in patients with darker skin or a history of adverse reactions to light-based therapies.

Ideal candidates for IPL treatment of rosacea are those with persistent erythema and visible telangiectasias who have not achieved satisfactory improvement with topical therapies alone. Patients with the erythematotelangiectatic phenotype, characterized primarily by vascular manifestations rather than inflammatory papules and pustules, respond particularly well to IPL. Those with fair to medium skin tones generally achieve the best results with the lowest risk of pigmentary complications, though IPL can be safely performed in darker skin types with appropriate parameter adjustments.

Relative contraindications to IPL treatment include active skin infections in the treatment area, recent or significant sun exposure or tanning, use of photosensitizing medications, pregnancy, and a history of keloid formation or abnormal wound healing. Patients taking isotretinoin should defer treatment until at least six months after discontinuation due to the increased risk of scarring and delayed wound healing associated with this medication. Those with unrealistic expectations regarding outcomes or who are unable to comply with post-treatment care instructions may not be appropriate candidates.

A thorough consultation and assessment are essential before initiating IPL therapy. Dr. Munib's approach at The Pur Health includes detailed evaluation of the patient's rosacea phenotype, identification of triggering factors, review of previous treatments and their efficacy, assessment of skin type and photosensitivity, discussion of realistic treatment goals and expected outcomes, and development of a comprehensive management plan that may include IPL as one component of a multimodal approach.

Appropriate post-treatment care is critical for optimizing outcomes and minimizing the risk of adverse effects following IPL therapy. Immediately after treatment, gentle cleansing with mild, non-irritating products and application of bland emollients help support the skin barrier during the acute healing phase. Strict photoprotection with broad-spectrum sunscreen of SPF 30 or higher is essential, as treated skin is more vulnerable to UV-induced pigmentation changes for several weeks following treatment.

Patients should avoid activities that increase facial blood flow and temperature, such as vigorous exercise, hot showers, saunas, or alcohol consumption, for at least 24 to 48 hours after treatment. These activities can exacerbate post-treatment erythema and edema and may theoretically interfere with the intended vascular effects of the treatment. Similarly, potentially irritating topical agents including retinoids, alpha hydroxy acids, and certain acne medications should be temporarily discontinued until any treatment-related irritation has resolved.

Common transient side effects include erythema, edema, and a sensation of warmth or mild burning, all of which typically resolve within one to three days. Patients may notice temporary darkening or crusting of treated telangiectasias, which should not be picked or manipulated as this can lead to scarring. More concerning adverse effects, though rare when treatment is performed appropriately, include blistering, hyperpigmentation or hypopigmentation, and prolonged or severe erythema. Any of these findings warrant immediate evaluation and may require adjustment of treatment parameters for subsequent sessions or discontinuation of IPL therapy.

While IPL effectively addresses the vascular manifestations of rosacea, optimal management of this chronic condition requires a multimodal approach that includes trigger identification and avoidance, appropriate skincare practices, and when necessary, topical or systemic anti-inflammatory medications. Dr. Munib's philosophy at The Pur Health emphasizes that IPL should be viewed as one tool within a comprehensive treatment strategy rather than a standalone intervention.

For patients with concurrent inflammatory lesions, combining IPL with topical therapies such as metronidazole, azelaic acid, or ivermectin may provide more complete symptom control than either treatment alone. Those with significant flushing triggered by specific factors may benefit from identifying and avoiding these triggers while using IPL to reduce the baseline vascular reactivity that makes flushing more pronounced. Maintaining a gentle skincare routine with products formulated for sensitive skin helps support the skin barrier and may reduce inflammatory flares between IPL maintenance treatments.

Patient education regarding the chronic nature of rosacea and the importance of ongoing management is essential for achieving sustained improvement. While IPL can produce dramatic reduction in erythema and telangiectasias, it does not cure the underlying predisposition to rosacea, and new vascular changes can develop over time if the condition is not properly managed. Setting realistic expectations regarding the need for potential maintenance treatments and continued trigger avoidance helps ensure patient satisfaction and optimal long-term outcomes.

Research continues to refine our understanding of optimal IPL parameters, combination treatment approaches, and long-term outcomes in rosacea management. Ongoing studies are examining novel wavelength combinations, the role of adjunctive therapies such as topical antioxidants to enhance treatment response, predictors of treatment success to improve patient selection, and strategies for maintaining improvement and minimizing the need for repeated interventions.

The development of more sophisticated outcome measures, including objective assessment tools such as colorimetry and dermoscopy, is improving our ability to quantify treatment effects and compare different therapeutic approaches. Standardized photography protocols and digital image analysis allow for more precise documentation of vascular changes and help establish evidence-based guidelines for treatment parameters and protocols.

As the evidence base expands and technology evolves, the role of IPL in rosacea management will continue to be refined. Dr. Munib's commitment to evidence-based practice at The Pur Health ensures that patients benefit from the most current understanding of IPL efficacy, optimal treatment protocols, and integration of light-based therapies within comprehensive rosacea management strategies.

1. Shi H, Zhang E, Zhang M, Lin T. Narrow-Band Intense Pulsed Light as Treatment for Erythematotelangiectatic Rosacea: A Retrospective Study. Journal of Drugs in Dermatology: JDD. 2023;22(11):1095-1098. doi:10.36849/JDD.4920.
2. Piccolo D, Fusco I, Zingoni T, Conforti C. Effective Treatment of Rosacea and Other Vascular Lesions Using Intense Pulsed Light System Emitting Vascular Chromophore-Specific Wavelengths: A Clinical and Dermoscopical Analysis. Journal of Clinical Medicine. 2024;13(6):1646. doi:10.3390/jcm13061646.
3. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of Rosacea With Intense Pulsed Light: Significant Improvement and Long-Lasting Results. The British Journal of Dermatology. 2008;159(3):628-32. doi:10.1111/j.1365-2133.2008.08702.x.
4. Van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for Rosacea Based on the Phenotype Approach: An Updated Systematic Review Including GRADE Assessments. The British Journal of Dermatology. 2019;181(1):65-79. doi:10.1111/bjd.17590.
5. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for Rosacea. The Cochrane Database of Systematic Reviews. 2015;(4):CD003262. doi:10.1002/14651858.CD003262.pub5.
6. Ruan J, Zheng Y, Cai S. Efficacy and Safety Comparison Between Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Treating Erythematotelangiectatic Rosacea. Lasers in Medical Science. 2024;39(1):146. doi:10.1007/s10103-024-04098-9.
7. Bao N, Gu T, Zeng J, et al. Combined Therapy of 5-Aminolevulinic Acid Photodynamic Therapy and Intense Pulsed Light for Rosacea. Lasers in Medical Science. 2022;38(1):17. doi:10.1007/s10103-022-03685-y.
8. Tsunoda K, Akasaka K, Akasaka T, Amano H. Successful Treatment of Erythematotelangiectatic Rosacea With Intense Pulsed Light: Report of 13 Cases. The Journal of Dermatology. 2018;45(9):1113-1116. doi:10.1111/1346-8138.14513.
9. Liu X, Qi X, He Y, Xiang L, Wang A. Effect of Intense Pulsed Light Combined With 3% Tranexamic Acid for Facial Erythema Associated With Acne Vulgaris and Rosacea. Lasers in Surgery and Medicine. 2025;57(6):490-495. doi:10.1002/lsm.70029.
10. Cai Y, Zhu Y, Wang Y, Xiang W. Intense Pulsed Light Treatment for Inflammatory Skin Diseases: A Review. Lasers in Medical Science. 2022;37(8):3085-3105. doi:10.1007/s10103-022-03620-1.
11. Jiang P, Liu Y, Zhang J, et al. Mast Cell Stabilization: New Mechanism Underlying the Therapeutic Effect of Intense Pulsed Light on Rosacea. Inflammation Research: Official Journal of the European Histamine Research Society. 2023;72(1):75-88. doi:10.1007/s00011-022-01635-6.